Table.
Factors associated with SARS-CoV-2 infection after vaccination in patients with SLE
| SARS-CoV-2 infection (n=44) | No SARS-CoV-2 infection (n=119) | p value | ||
|---|---|---|---|---|
| Received additional vaccine dose | 28 (64%) | 97 (82%) | 0·022 | |
| Time from terminal vaccine dose to infection or last follow-up, days | 142·1 (87·8) | 164·7 (88·8) | 0·14 | |
| Age, years | 42·6 (12·6) | 44·7 (13·9) | 0·43 | |
| Sex | ||||
| Female | 41 (93%) | 108 (91%) | 0·76 | |
| Male | 3 (7%) | 11 (9%) | .. | |
| Race | ||||
| White | 26 (59%) | 38 (32%) | 0·0020 | |
| Black | 5 (11%) | 34 (29%) | .. | |
| Asian | 9 (20%) | 30 (25%) | .. | |
| Other | 4 (9%) | 17 (14%) | .. | |
| Ethnicity | ||||
| Hispanic or Latinx | 17 (39%) | 39 (33%) | 0·58 | |
| Non-Hispanic or Latinx | 27 (61%) | 80 (67%) | .. | |
| Initial mRNA COVID-19 vaccine | 42 (95%) | 115 (97%) | 0·66 | |
| Initial vector-based vaccine | 2 (5%) | 4 (3%) | .. | |
| History of lupus nephritis | 22 (50) | 58 (49%) | 1·0 | |
| Medications at time of last vaccine | ||||
| Hydroxychloroquine | 40 (91%) | 100 (84%) | 0·32 | |
| Glucocorticoids | 14 (32%) | 42 (35%) | 0·85 | |
| ≥1 immunosuppressant | 24 (55%) | 59 (50%) | 0·60 | |
| Glucocorticoids plus immunosuppressant | 13 (30%) | 34 (29%) | 1·00 | |
| Combination of immunosuppressants | 11 (25%) | 17 (14%) | 0·16 | |
| COVID-19 treatment | ||||
| Monoclonal antibodies | 3 (7%) | NA | .. | |
| Ritonavir-boosted nirmatrelvir | 3 (7%) | NA | .. | |
| Remdesivir | 1 (2%) | NA | .. | |
Data are n (%) or mean (SD). SLE=systemic lupus erythematosus. NA=not applicable.